← All Barinthus Biotherapeutics PLC filings

Barinthus Biotherapeutics PLC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
BRNS
Barinthus Biotherapeutics PLC
SCHEDULE: Oxford Science Enterprises Sells All Barinthus Biotherapeutics Shares
Oxford Science Enterprises plc has reported the divestment of all its holdings in Barinthus Biotherapeutics plc, reducing its beneficial ownership to zero.
NASDAQ
BRNS
Barinthus Biotherapeutics PLC
SCHEDULE 13G/A: Frank W. Cawood Discloses 8.4% Stake in Barinthus Biotherapeutics Plc
Frank W. Cawood has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% of Barinthus Biotherapeutics Plc's American Depositary Shares as of December 31, 2024.